{"id":"NCT00089843","sponsor":"Massachusetts General Hospital","briefTitle":"Bone Loss in Women With Anorexia Nervosa","officialTitle":"IGF-1 and Bone Loss in Women Anorexia Nervosa","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2003-06","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2004-08-17","resultsPosted":"2012-06-01","lastUpdate":"2020-09-02"},"enrollment":77,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Anorexia Nervosa"],"interventions":[{"type":"DRUG","name":"Testosterone","otherNames":["Intrinsa"]},{"type":"DRUG","name":"Actonel (risedronate)","otherNames":["Actonel"]},{"type":"DRUG","name":"Placebo Actonel (risedronate)","otherNames":[]},{"type":"DRUG","name":"Placebo testosterone","otherNames":[]}],"arms":[{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"3","type":"ACTIVE_COMPARATOR"},{"label":"4","type":"ACTIVE_COMPARATOR"},{"label":"1","type":"PLACEBO_COMPARATOR"}],"summary":"Women with Anorexia Nervosa have been found to have low bone density. The study will determine whether administration of low doses of a natural hormone, testosterone and/or risedronate, a medication to help prevent bone breakdown will improve or prevent bone loss in this condition.","primaryOutcome":{"measure":"Bone Mineral Density","timeFrame":"Baseline and 12 months","effectByArm":[{"arm":"Actonel (Risedronate) 35 mg Weekly","deltaMin":3.2,"sd":null},{"arm":"Testosterone","deltaMin":-0.6,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"},{"comp":"OG001","p":"0.41"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["17592924"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":19},"commonTop":["Mild increase in acne or oily skin","Mild irritation at patch site","Mild increase in body hair growth","Reflux","Myalgias"]}}